Imarsa

Fulvestrant, the active ingredient in Imarsa, is a selective estrogen receptor degrader (SERD) presented as an injectable solution for intramuscular use. It blocks estrogen signaling and promotes receptor down‑regulation, providing therapeutic benefit in metastatic estrogen receptor‑positive breast cancer for adult patients.

GNH USA supplies Imarsa as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide, with robust cold‑chain logistics and validated manufacturing processes.

Fulvestrant acts on estrogen‑driven breast cancer pathways and is indicated for advanced disease management. - Metastatic estrogen receptor‑positive breast cancer: reduces tumor growth and disease progression. - Hormone receptor‑positive advanced breast cancer: offers an alternative after prior endocrine therapy failure. - Postmenopausal women with ER‑positive disease: provides estrogen receptor degradation to control cancer spread.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Hot flashes: transient sensation of warmth. - Nausea: occasional upset stomach. - Fatigue: general tiredness. - Arthralgia: joint aches. - Headache: mild to moderate.

Serious or Rare Side Effects: - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Pulmonary embolism: sudden shortness of breath or chest pain. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Tumor pain: worsening pain at metastatic sites. - Hypercalcemia: elevated calcium levels causing confusion or weakness. - QT interval prolongation: cardiac rhythm disturbance.

Before initiating therapy, consider the following precautions: - Liver function monitoring: assess hepatic enzymes regularly. - Thromboembolic risk assessment: evaluate history of clotting disorders. - Hypersensitivity evaluation: check for known allergy to fulvestrant or excipients. - Bone health: use caution in patients with severe osteoporosis. - Pregnancy avoidance: contraindicated in pregnancy; ensure effective contraception. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Fulvestrant may interact with other medicines; review patient medication lists. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase fulvestrant exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Concurrent estrogen‑containing therapies: antagonistic effect. Moderate Interactions (Monitor Closely): - Warfarin: monitor INR for altered anticoagulation. - Statins metabolized by CYP3A4: observe for increased statin levels. - Antihypertensives: watch for blood pressure changes. - Herbal supplements (e.g., St. John's wort): may affect metabolism. - Anticoagulants: assess bleeding risk.